XML 106 R60.htm IDEA: XBRL DOCUMENT
v3.25.1

Significant events for the years ended December 31, 2022, 2023 and 2024 and subsequent events - For the year ended 2022 (Details) € / shares in Units, € in Thousands, $ in Millions |  |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 8 Months Ended | 12 Months Ended | 121 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 24, 2023 EUR (€) € / shares shares | Oct. 24, 2023 USD ($) shares | Feb. 22, 2023 € / shares shares | Oct. 11, 2022 EUR (€) | Sep. 07, 2022 € / shares shares | Sep. 02, 2022 EUR (€) transaction € / shares shares | Dec. 01, 2021 EUR (€) | Feb. 23, 2024 EUR (€) | Aug. 31, 2022 EUR (€) | Jun. 30, 2023 EUR (€) | Dec. 12, 2022 | Dec. 31, 2024 EUR (€) € / shares | Dec. 31, 2023 EUR (€) € / shares shares | Dec. 31, 2022 EUR (€) € / shares shares | Dec. 31, 2021 EUR (€) | Dec. 31, 2023 EUR (€) € / shares | Nov. 19, 2024 € / shares | May 24, 2023 € / shares | Apr. 01, 2022 EUR (€) | Nov. 25, 2021 EUR (€)
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash advances and loans made to (reimbursed from) hospitals |  |  |  |  |  |  |  |  |  |  |  | € 0 | € 0 | € (3,302) |  |  |  |  |  |
Capital increases | € 223,300 | $ 235.8 |  |  |  |  |  |  |  |  |  | € 0 | € 353,377 | € 46,231 |  | € 557,200 |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares | 20,325,500 | 20,325,500 | 20,000,000 |  | 5,530,000 |  |  |  |  |  |  |  | 40,325,500 | 5,530,000 |  |  |  |  |  |
Par value per share (in euro per share) | € / shares | € 0.01 |  | € 0.01 |  | € 0.01 |  |  |  |  |  |  | € 0.01 | € 0.01 | € 0.01 |  | € 0.01 | € 0.01 | € 0.01 |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  | € 6.50 |  | € 8.36 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net proceeds from sale of royalty certificates |  |  |  |  |  | € 2,931 |  |  |  |  |  | € 0 | € 0 | € 2,931 |  | € 2,900 |  |  |  |
Royalty certificate, percentage of future sales |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty certificate, maximum amount |  |  |  |  |  | € 172,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issue related cost |  |  |  |  |  |  |  |  |  |  |  |  | 28,111 | 3,280 |  |  |  |  |  |
Cash advances and loans made to CRO |  |  |  | € 12,187 |  |  |  | € 5,538 |  | € 1,620 |  | 231 | 1,620 | 12,187 |  |  |  |  |  |
Advances related to CRO contracts |  |  |  |  |  |  |  |  |  |  |  | 4,929 | 12,172 | 10,471 |  | € 12,172 |  |  |  |
€49.2 million cross-over financing, september 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, amount |  |  |  |  |  | € 49,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial agreement, number of transactions | transaction |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increases |  |  |  |  |  | € 46,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increase from issuance of ordinary shares (in shares) | shares |  |  |  |  |  | 5,530,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Par value per share (in euro per share) | € / shares |  |  |  |  |  | € 0.01 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issuance, percentage of current share capital |  |  | 89.60% |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issuance, subscripion price per share (in euro per share) | € / shares |  |  |  |  |  | € 8.36 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net proceeds from sale of royalty certificates |  |  |  |  |  | € 2,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty certificate, percentage of future sales |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty certificate, maximum amount |  |  |  |  |  | € 172,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
€49.2 million cross-over financing, september 2022 | Share premium |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issue related cost |  |  |  |  |  | € 3,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research agreement with University Hospital Center of Nice |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash advances and loans made to (reimbursed from) hospitals |  |  |  |  |  |  |  |  | € (3,302) |  |  |  |  |  | € 4,000 |  |  |  |  |
Other expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 698 |  |  |  |  |  |
AGA 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Compensation expenses |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,026 |  |  |  |  |  |
Social taxes related to AGAs |  |  |  |  |  |  |  |  |  |  |  |  |  | 205 |  |  |  |  |  |
Wittycel SAS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment loss recognised in profit or loss, goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,586 |  |  |  |  |  |
Impairment |  |  |  |  |  |  |  |  |  |  |  | € 0 | € 0 | 45 |  |  |  |  |  |
Intangible assets with indefinite useful life |  |  |  |  |  |  |  |  |  |  |  |  |  | € 0 |  |  |  |  |  |
Prosynergia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan granted |  |  |  |  |  |  | € 1,400 |  |  |  |  |  |  |  |  |  |  |  |  |
Prosynergia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash prepayment made in 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 325 | € 325
Cash payment made in 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,925 |
Earn-out, maximum amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000 |
Loan granted to Prosynergia in 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 1,400 |
Prosynergia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about borrowings [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proportion of ownership interest in subsidiary |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |

X
- Definition Cash Advances And Loans Made To (Reimbursed From) Hospitals + References No definition available. + Details
Name: | abvx_CashAdvancesAndLoansMadeToReimbursedFromHospitals
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash Prepayment, Assets Acquisitions + References No definition available. + Details
Name: | abvx_CashPrepaymentAssetsAcquisitions
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash Transferred, Assets Acquisitions + References No definition available. + Details
Name: | abvx_CashTransferredAssetsAcquisitions
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Earn-Out, Maximum Amount + References No definition available. + Details
Name: | abvx_EarnOutMaximumAmount
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Issuance, Percentage Of Current Share Capital + References No definition available. + Details
Name: | abvx_EquityIssuancePercentageOfCurrentShareCapital
Namespace Prefix: | abvx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Issuance, Subscription Price Per Share + References No definition available. + Details
Name: | abvx_EquityIssuanceSubscriptionPricePerShare
Namespace Prefix: | abvx_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes + References No definition available. + Details
Name: | abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Financial Agreement, Amount + References No definition available. + Details
Name: | abvx_FinancialAgreementAmount
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Financial Agreement, Number Of Transactions + References No definition available. + Details
Name: | abvx_FinancialAgreementNumberOfTransactions
Namespace Prefix: | abvx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase + References No definition available. + Details
Name: | abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease
Namespace Prefix: | abvx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loan Granted, Assets Acquisitions + References No definition available. + Details
Name: | abvx_LoanGrantedAssetsAcquisitions
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Net Proceeds From Sale Of Royalty Certificates + References No definition available. + Details
Name: | abvx_NetProceedsFromSaleOfRoyaltyCertificates
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-Current Advances To CRO Contracts + References No definition available. + Details
Name: | abvx_NonCurrentAdvancesToCROContracts
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payments For Advances Made to Contract Research Organizations + References No definition available. + Details
Name: | abvx_PaymentsForAdvancesMadeToContractResearchOrganizations
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Certificate, Maximum Amount + References No definition available. + Details
Name: | abvx_RoyaltyCertificateMaximumAmount
Namespace Prefix: | abvx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Royalty Certificate, Percentage Of Future Sales + References No definition available. + Details
Name: | abvx_RoyaltyCertificatePercentageOfFutureSales
Namespace Prefix: | abvx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash advances and loans made to other parties (other than advances and loans made by a financial institution), classified as investing activities. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CashAdvancesAndLoansMadeToOtherPartiesClassifiedAsInvestingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 51 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2024-01-01 -Paragraph B67 -Subparagraph d -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B -URIDate 2024-03-27 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2024-01-01 -Paragraph 118 -Subparagraph e -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_iv&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2024-01-01 -Paragraph 134 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_b&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2024-01-01 -Paragraph 135 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_b&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2024-01-01 -Paragraph 122 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The nominal value per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 79 -Subparagraph a -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ParValuePerShare
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from issuing shares. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromIssuingShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cost related to the issuance of shares. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ShareIssueRelatedCost
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | abvx_FinancialAgreementAxis=abvx_A49.2MillionCrossOverFinancingSeptember2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_PrincipalAgreementsAxis=abvx_ResearchAgreementWithUniversityHospitalCenterOfNiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=abvx_AGA2021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis=abvx_WittycelSASABX196Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abvx_ProsynergiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | abvx_AssetsAcquisitionsAxis=abvx_ProsynergiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=abvx_ProsynergiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |